Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
RESEARCH TOOLSreports
Holding NTLA?
Track your performance easily
See the Price Targets and Ratings of:
NTLA Analyst Ratings
Strong Buy
17 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NTLA Stock 12 Month Forecast
Average Price Target
$51.53
▲(285.13% Upside)
| Highest Price Target$91.00 | Average Price Target$51.53 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
Reiterated
11/26/24
Truist Financial
Assigned
11/18/24
Chardan Capital
Reiterated
11/18/24
Evercore ISI
Assigned
11/18/24
Canaccord Genuity
Reiterated
11/18/24
Citi
Reiterated
11/18/24
JMP Securities
Reiterated
11/18/24
TD Cowen
Assigned
11/18/24
Morgan Stanley
Reiterated
11/17/24
Wells Fargo
Reiterated
11/17/24
Leerink Partners
$51→$55
Buy
311.06%
Upside
Reiterated
11/16/24
Intellia Therapeutics' NTLA-2001 Shows Promising Potential with Positive Phase 1 Data and Accelerated Phase 3 Enrollment
Oppenheimer
$60
Buy
348.43%
Upside
Assigned
11/11/24
Intellia Therapeutics price target lowered to $60 from $70 at OppenheimerIntellia Therapeutics price target lowered to $60 from $70 at Oppenheimer
Barclays
$76→$55
Buy
311.06%
Upside
Reiterated
11/08/24
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan
$55→$45
Buy
236.32%
Upside
Reiterated
11/08/24
Intellia Therapeutics (NTLA) PT Lowered to $45 at JPMorganJPMorgan analyst Brian Cheng lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $45.00 (from $55.00) while maintaining a Overweight rating.
Stifel Nicolaus
$64→$54
Buy
303.59%
Upside
Reiterated
11/07/24
Stifel reiterates Buy Rating on Intellia Therapeutics (NTLA)Stifel analyst Dae Gon Ha reiterated a Buy rating and $54.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
Best Analysts Covering Intellia Therapeutics
Which Analyst Should I Follow If I Want to Buy NTLA and Sell After:
1 Month
xxx
Success Rate
15/38 ratings generated profit
Average Return
+2.74%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 39.47% of your transactions generating a profit, with an average return of +2.74% per trade.
3 Months
xxx
Success Rate
15/38 ratings generated profit
Average Return
+13.49%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 39.47% of your transactions generating a profit, with an average return of +13.49% per trade.
1 Year
Success Rate
13/38 ratings generated profit
Average Return
+88.05%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 34.21% of your transactions generating a profit, with an average return of +88.05% per trade.
2 Years
xxx
Success Rate
14/38 ratings generated profit
Average Return
+109.60%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 36.84% of your transactions generating a profit, with an average return of +109.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NTLA Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
22
21
13
26
36
Buy
6
8
5
7
7
Hold
7
6
3
7
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
35
21
40
52
Each month's total comprises the sum of three months' worth of ratings.
NTLA Financial Forecast
NTLA Stock Forecast FAQ
What is NTLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is $51.53.
What is NTLA’s upside potential, based on the analysts’ average price target?
Intellia Therapeutics has 285.13% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NTLA a Buy, Sell or Hold?
Intellia Therapeutics has a consensus rating of Strong Buy which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.
What is Intellia Therapeutics’s price target?
The average price target for Intellia Therapeutics is $51.53. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $91.00 ,the lowest forecast is $14.00. The average price target represents 285.13% Increase from the current price of $13.38.
The highest analyst price target is $91.00 ,the lowest forecast is $14.00. The average price target represents 285.13% Increase from the current price of $13.38.
What do analysts say about Intellia Therapeutics?
Intellia Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
How can I buy shares of NTLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.